{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:48:14Z","timestamp":1787777294861,"version":"build-2784847793"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T00:00:00Z","timestamp":1525737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81500030"],"award-info":[{"award-number":["81500030"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2016A030313272"],"award-info":[{"award-number":["2016A030313272"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2016A030313277"],"award-info":[{"award-number":["2016A030313277"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2017A030313573"],"award-info":[{"award-number":["2017A030313573"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long-term survival rates for patients with stage III\u2013IV Hodgkin lymphoma, or advanced Hodgkin lymphoma (aHL), have increased substantially since the 1960s. Because large-scale research of aHL is rare, we aimed to demonstrate the differences in incidence and survival of aHL according to four patient variables in recent decades, with a focus on the outcomes of treatment of aHL and the advancement of public health care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Data on aHL cases diagnosed during 1984\u20132013 were extracted from the Surveillance, Epidemiology, and End Results Program database. Relative survival, Kaplan-Meier, and Cox proportional hazards regression analyses were performed to identify prognosis indicators for aHL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The incidence rates for aHL were 1.1, 0.8, and 1.0 per 100,000 in the first, second, and third decades, respectively, during 1984\u20132013. The 120-month relative survival rate improved continuously in each decade from 58.5% to 64.6% to 72.1%. In addition, disparities in the 120-month relative survival rate between male and female patients and among patients of different races narrowed over time. The difference in long-term survival rate between the poor (medium and high poverty) and rich (low poverty) groups narrowed across the 3 decades.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The long-term survival rate for patients with aHL increased in each decade, whereas survival rate disparities according to sex, race, and socioeconomic status narrowed, except for older patients aged &amp;gt;60 years and the high-poverty group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>Long-term survival rates of patients with advanced Hodgkin lymphoma were elaborated in this article. The disparities according to sex, race, and socioeconomic status of survival condition were analyzed and showed the development of the public health care system and modern medicine technology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0541","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T12:05:27Z","timestamp":1525781127000},"page":"1328-1336","source":"Crossref","is-referenced-by-count":24,"title":["Long-Term Survival Rates of Patients with Stage III\u2013IV Hodgkin Lymphoma According to Age, Sex, Race, and Socioeconomic Status, 1984\u20132013"],"prefix":"10.1093","volume":"23","author":[{"given":"Yushi","family":"Li","sequence":"first","affiliation":[{"name":"Department of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhuan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuncong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqing","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"key":"2021122511252086700_onco12467-bib-0001","year":"2016"},{"key":"2021122511252086700_onco12467-bib-0002","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ncponc1186","article-title":"Treatment of Hodgkin lymphoma: The past, present, and future","volume":"5","author":"Evens","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"2021122511252086700_onco12467-bib-0003","doi-asserted-by":"crossref","first-page":"554","DOI":"10.6004\/jnccn.2015.0075","article-title":"Hodgkin lymphoma, version 2.2015","volume":"13","author":"Hoppe","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122511252086700_onco12467-bib-0004","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2021122511252086700_onco12467-bib-0005","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood-2014-07-537480","article-title":"Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma","volume":"125","author":"Connors","year":"2015","journal-title":"Blood"},{"key":"2021122511252086700_onco12467-bib-0006","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/bmj.3.5713.7","article-title":"Combination chemotherapy in generalized Hodgkin's disease","volume":"3","author":"Nicholson","year":"1970","journal-title":"Br Med J"},{"key":"2021122511252086700_onco12467-bib-0007","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/bjh.14567","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: An analysis of the Swedish Lymphoma Registry","volume":"177","author":"Molin","year":"2017","journal-title":"Br J Haematol"},{"key":"2021122511252086700_onco12467-bib-0008","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/asheducation-2016.1.390","article-title":"Checkpoint inhibition and cellular immunotherapy in lymphoma","volume":"2016","author":"Lulla","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2021122511252086700_onco12467-bib-0009","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1007\/s00330-016-4470-8","article-title":"CT-based texture analysis potentially provides prognostic information complementary to interim FDG-PET for patients with Hodgkin's and aggressive non-Hodgkin's lymphomas","volume":"27","author":"Ganeshan","year":"2017","journal-title":"Eur Radiol"},{"key":"2021122511252086700_onco12467-bib-0010","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/bjc.2012.228","article-title":"Long-term survival after treatment for Hodgkin's disease (1973\u20132002): Improved survival with successive 10-year cohorts","volume":"107","author":"Bessell","year":"2012","journal-title":"Br J Cancer"},{"key":"2021122511252086700_onco12467-bib-0011","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/j.seminhematol.2016.05.004","article-title":"Treatment of early-stage Hodgkin lymphoma","volume":"53","author":"Engert","year":"2016","journal-title":"Semin Hematol"},{"key":"2021122511252086700_onco12467-bib-0012","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/1055-9965.EPI-15-0756","article-title":"Impact of treatment and insurance on socioeconomic disparities in survival after adolescent and young adult Hodgkin lymphoma: A population-based study","volume":"25","author":"Keegan","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021122511252086700_onco12467-bib-0013","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/annonc\/mdr578","article-title":"Racial disparities in Hodgkin's lymphoma: A comprehensive population-based analysis","volume":"23","author":"Evens","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122511252086700_onco12467-bib-0014","first-page":"1197","article-title":"Prognostic significance of CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma [in Chinese]","volume":"27","author":"Fu","year":"2008","journal-title":"Ai Zheng"},{"key":"2021122511252086700_onco12467-bib-0015","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/CCO.0b013e32832f3ca3","article-title":"The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma","volume":"21","author":"Maeda","year":"2009","journal-title":"Curr Opin Oncol"},{"key":"2021122511252086700_onco12467-bib-0016","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11899-010-0052-z","article-title":"Does rituximab have a place in treating classic Hodgkin lymphoma?","volume":"5","author":"Oki","year":"2010","journal-title":"Curr Hematol Malig Rep"},{"key":"2021122511252086700_onco12467-bib-0017","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ajh.24272","article-title":"Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Ansell","year":"2016","journal-title":"Am J Hematol"},{"key":"2021122511252086700_onco12467-bib-0018","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","article-title":"A retrospective multicenter analysis of elderly Hodgkin lymphoma: Outcomes and prognostic factors in the modern era","volume":"119","author":"Evens","year":"2012","journal-title":"Blood"},{"key":"2021122511252086700_onco12467-bib-0019","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: A comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br J Haematol"},{"key":"2021122511252086700_onco12467-bib-0020","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","article-title":"Bleomycin in older early-stage favorable Hodgkin lymphoma patients: Analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials","volume":"127","author":"Boll","year":"2016","journal-title":"Blood"},{"key":"2021122511252086700_onco12467-bib-0021","doi-asserted-by":"crossref","first-page":"8522","DOI":"10.18632\/oncotarget.14338","article-title":"Estrogen receptor \u03b2 ligation inhibits Hodgkin lymphoma growth by inducing autophagy","volume":"8","author":"Pierdominici","year":"2017","journal-title":"Oncotarget"},{"key":"2021122511252086700_onco12467-bib-0022","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.mce.2013.05.016","article-title":"Estrogen receptor \u03b1 and \u03b2 in the normal immune system and in lymphoid malignancies","volume":"375","author":"Yakimchuk","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"2021122511252086700_onco12467-bib-0023","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/cam4.655","article-title":"Improved survival time trends in Hodgkin's lymphoma","volume":"5","author":"Koshy","year":"2016","journal-title":"Cancer Med"},{"key":"2021122511252086700_onco12467-bib-0024","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2005.05.2746","article-title":"Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: Long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials","volume":"24","author":"Noordijk","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122511252086700_onco12467-bib-0025","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2006.09.0936","article-title":"Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma","volume":"25","author":"Hodgson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122511252086700_onco12467-bib-0026","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.V97.4.835","article-title":"An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs","volume":"97","author":"Gottschalk","year":"2001","journal-title":"Blood"},{"key":"2021122511252086700_onco12467-bib-0027","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/aje\/kws212","article-title":"Perinatal and family risk factors for Hodgkin lymphoma in childhood through young adulthood","volume":"176","author":"Crump","year":"2012","journal-title":"Am J Epidemiol"},{"key":"2021122511252086700_onco12467-bib-0028","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/(SICI)1097-0215(19970207)70:4<375::AID-IJC1>3.0.CO;2-T","article-title":"Epstein-Barr virus-associated Hodgkin's disease: Epidemiologic characteristics in international data","volume":"70","author":"Glaser","year":"1997","journal-title":"Int J Cancer"},{"key":"2021122511252086700_onco12467-bib-0029","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s11864-013-0231-y","article-title":"EBV-related lymphomas: New approaches to treatment","volume":"14","author":"Kanakry","year":"2013","journal-title":"Curr Treat Options Oncol"},{"key":"2021122511252086700_onco12467-bib-0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.beha.2012.01.005","article-title":"EBV-associated lymphomas in adults","volume":"25","author":"Roschewski","year":"2012","journal-title":"Best Pract Res Clin Haematol"},{"key":"2021122511252086700_onco12467-bib-0031","doi-asserted-by":"crossref","first-page":"2138259","DOI":"10.1155\/2016\/2138259","article-title":"Risk of cancer among commercially insured HIV-infected adults on antiretroviral therapy","volume":"2016","author":"Lee","year":"2016","journal-title":"J Cancer Epidemiol"},{"key":"2021122511252086700_onco12467-bib-0032","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/CCO.0b013e3283560697","article-title":"Impact of highly effective antiretroviral therapy on the risk for Hodgkin lymphoma among people with human immunodeficiency virus infection","volume":"24","author":"Goedert","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"2021122511252086700_onco12467-bib-0033","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2013.53.1194","article-title":"Treatment of Hodgkin lymphoma: A 50-year perspective","volume":"32","author":"Canellos","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0541","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0541","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/11\/1328\/41914457\/oncolo_23_11_1328.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/11\/1328\/41914457\/oncolo_23_11_1328.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T06:26:50Z","timestamp":1640413610000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/11\/1328\/6439722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,8]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,5,8]]},"published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0541","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,11,1]]},"published":{"date-parts":[[2018,5,8]]}}}